2024
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study
Carr T, Moore W, Kraft M, Brusselle G, Castro M, Chupp G, Wechsler M, Hunter G, Lindsley A, Llanos J, Burke L, Chandarana S, Ambrose C. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study. Advances In Therapy 2024, 41: 2978-2990. PMID: 38802635, PMCID: PMC11213736, DOI: 10.1007/s12325-024-02889-8.Peer-Reviewed Original ResearchAnnualized asthma exacerbation rateClinically relevant subgroupsEfficacy of tezepelumabBaseline patient characteristicsUncontrolled asthmaClinically relevant subgroups of patientsPatient characteristicsStandard-of-care therapyRelevant subgroups of patientsTezepelumab reduced exacerbationsRelevant subgroupsPlacebo-controlled studyAsthma exacerbation rateSubgroup of patientsReducing asthma exacerbationsBody mass indexPost hoc analysisNSAID sensitivityDouble-blindExacerbation rateTezepelumabSmoking historyPatient subgroupsPlaceboIntroductionMany patients
2023
EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA WITH COMORBID GASTROESOPHAGEAL REFLUX DISEASE: A POOLED ANALYSIS OF THE PATHWAY AND NAVIGATOR STUDIES
MOORE W, LUGOGO N, CHUPP G, MARTIN N, AMBROSE C, COOK W, ACKERT J. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA WITH COMORBID GASTROESOPHAGEAL REFLUX DISEASE: A POOLED ANALYSIS OF THE PATHWAY AND NAVIGATOR STUDIES. CHEST Journal 2023, 164: a4-a7. DOI: 10.1016/j.chest.2023.07.073.Peer-Reviewed Original ResearchEfficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials
Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, Ambrose C, Hellqvist Å, Roseti S, Molfino N, Llanos J, Martin N, Bowen K, Griffiths J, Parnes J, Colice G. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. American Journal Of Respiratory And Critical Care Medicine 2023, 208: 13-24. PMID: 37015033, PMCID: PMC10870853, DOI: 10.1164/rccm.202210-2005oc.Peer-Reviewed Original ResearchConceptsAsthma exacerbation rateUncontrolled asthmaExacerbation rateSecondary outcomesClinical trialsOverall populationRelevant subgroupsMeaningful reductionEfficacy of tezepelumabExacerbation-related hospitalizationsSafety of tezepelumabPlacebo-controlled trialEmergency department visitsInflammatory biomarker levelsNitric oxide levelsAdverse eventsAllergy statusBaseline bloodClinical characteristicsDepartment visitsPooled analysisNAVIGATOR trialBiomarker levelsOxide levelsTezepelumabEfficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Sex: Results From the Phase 3 Navigator Study
Kraft M, Chupp G, Reeh K, Lindsley A, Cook B, Hunter G, Ambrose C. Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Sex: Results From the Phase 3 Navigator Study. 2023, a4751-a4751. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4751.Peer-Reviewed Original Research
2022
EFFICACY OF TEZEPELUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA DESPITE RECEIVING TREATMENT FOR MODERATE OR SEVERE DISEASE: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR STUDIES
CORREN J, WECHSLER M, CHUPP G, AMBROSE C, ROSETI S, HELLQVIST Å, ACKERT J, MARTIN N, COLICE G. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA DESPITE RECEIVING TREATMENT FOR MODERATE OR SEVERE DISEASE: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR STUDIES. CHEST Journal 2022, 162: a21-a22. DOI: 10.1016/j.chest.2022.08.018.Peer-Reviewed Original ResearchEfficacy of tezepelumabNAVIGATOR studyUncontrolled asthmaPooled analysisTezepelumabAsthmaPatientsDisease
2021
EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA GROUPED BY BASELINE BMI IN THE NAVIGATOR STUDY
Chupp G, Menzies-Gow A, Ambrose C, Cook W, Kmita K, Lindsley A, Llanos-Ackert J, Colice G, Lugogo N. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA GROUPED BY BASELINE BMI IN THE NAVIGATOR STUDY. CHEST Journal 2021, 160: a37-a40. DOI: 10.1016/j.chest.2021.07.078.Peer-Reviewed Original ResearchEfficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Grouped by Baseline Blood Eosinophil Count and Fractional Exhaled Nitric Oxide Level: Results from the NAVIGATOR Phase 3 Study
Corren J, Bourdin A, Chupp G, Israel E, Ambrose C, Llanos Ackert J, Kmita K, Cook B, Colice G, Menzies-Gow A. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Grouped by Baseline Blood Eosinophil Count and Fractional Exhaled Nitric Oxide Level: Results from the NAVIGATOR Phase 3 Study. 2021, a1198-a1198. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1198.Peer-Reviewed Original Research